AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts

blonca9
Mar 18
1 min read

Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulcerative colitis data that will be out in the fourth quarter and the opportunity there. He also highlights the company's PD-1 for oncology that is commercialized by GSK.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight